Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells
Authors:
Open Access
- 1 August 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 5049-5059
Abstract
Hypoxia is an inseparable component of the solid tumor as well as the bone marrow microenvironment. In this study, we investigated the effect of the novel polyethylene glycol (PEG)-poly L-lysine (PLL)-poly lactic-co-glycolic acid (PLGA) based nanoparticles (NPs) modified by transferrin (Tf) loaded with daunorubicin (DNR) (DNR-Tf-PEG-PLL-PLGA-NPs, abbreviated as DNR-Tf-NPs) on leukemia cells (K562) under hypoxia. In vitro and in vivo tests to determine the effect of the enhanced chemosensitivity were evaluated using the immunofluorescence, flow cytometry, 3,-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazoliumbromide assay, Western blot analysis, histopathological examination, and immunohistochemistry analysis. Under hypoxia, K562 cells were hypoxia-responsive with the inhibitory concentration 50% (IC50) of DNR increased, resulting in chemotherapy insensitivity. By targeting the transferrin receptor (TfR) on the surface of K562 cells, DNR-Tf-NPs led to an increased intracellular DNR level, enhancing drug sensitivity of K562 cells to DNR with a decreased IC50, even under hypoxia. We further detected the protein levels of hypoxia-inducible factor-1α (HIF-1α), Bcl-2, Bax, and caspase-3 in K562 cells. The results indicated that DNR-Tf-NPs downregulated HIF-1α and induced apoptosis to overcome hypoxia. In the xenograft model, injection of DNR-Tf-NPs significantly suppressed tumor growth, and the immunosignals of Ki67 in DNR-Tf-NPs group was significantly lower than the other groups. It was therefore concluded that DNR-Tf-NPs could be a promising candidate for enhancing drug sensitivity under hypoxia in tumor treatment.Keywords
This publication has 33 references indexed in Scilit:
- Cell Death SignalingCold Spring Harbor Perspectives in Biology, 2015
- HIF-1α pathway: role, regulation and intervention for cancer therapyActa Pharmaceutica Sinica B, 2015
- Cancer nanomedicine: from targeted delivery to combination therapyTrends in Molecular Medicine, 2015
- Nanomedicine therapeutic approaches to overcome cancer drug resistanceAdvanced Drug Delivery Reviews, 2013
- Wogonin inhibits tumor angiogenesis via degradation of HIF-1α proteinToxicology and Applied Pharmacology, 2013
- Transferrin and the Transferrin Receptor for the Targeted Delivery of Therapeutic Agents to the Brain and Cancer CellsTherapeutic Delivery, 2013
- BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinomaCancer Letters, 2007
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- The transferrin receptor: role in health and diseaseThe International Journal of Biochemistry & Cell Biology, 1999
- Changing bone marrow micro‐environment during development of acute myeloid leukaemia in ratsBritish Journal of Haematology, 1998